Drugs / NM-702
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00102050 | Apr 2003 → Apr 2006 | intermittent vascular claudication | Nissan Chemical Industries | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NM-702 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00102050 ↗ |
| Action | Inhibit | “NM-702 (phosphodiesterase inhibitor)” NCT00102050 ↗ |
| Route | Oral | “NM-702 oral tablets” NCT00102050 ↗ |